Psychopharmacology for the Violent Adolescent

Primary Care - Clinics in Office Practice

Volumn 33, Issue 2, 2006, Pages 531-544

  Calles Jr , Joseph L ^a,b  

^a Michigan State University   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; FLUOXETINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID; ZIPRASIDONE;

AGGRESSION; AKATHISIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY MASS; CHILD BEHAVIOR; CLINICAL TRIAL; COMORBIDITY; CONDUCT DISORDER; DEPRESSION; DISEASE EXACERBATION; DISSOCIATIVE DISORDER; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; HYPONATREMIA; HYPOTENSION; INTELLECTUAL IMPAIRMENT; LEARNING DISORDER; MOOD DISORDER; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDE; TERATOGENICITY; VIOLENCE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT MEDICINE; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; VIOLENCE;

EID: 33646532046     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2006.01.002     Document Type: Review

References (76)

1. Centers for Disease Control and Prevention. Surveillance summaries, May 21, 2004. MMWR 53 No. SS-2 (2004)
2. DeVoe J.F., Peter K., Kaufman P., et al. Indicators of school crime and safety: 2003. NCES 2004-004/NCJ 201257 (2004), US Departments of Education and Justice, Washington (DC)
3. Group for the Advancement of Psychiatry, Committee on Preventive Psychiatry. Violent behavior in children and youth: preventive intervention from a psychiatric perspective. J Am Acad Child Adolesc Psychiatry 38 3 (1999) 235-241
4. Vitiello B., and Stoff D.M. Subtypes of aggression and their relevance to child psychiatry. J Am Acad Child Adolesc Psychiatry 36 3 (1997) 307-315
5. Loeber R., Burke J.D., Lahey B.B., et al. Oppositional defiant and conduct disorder: a review of the past 10 years, Part I. J Am Acad Child Adolesc Psychiatry 39 12 (2000) 1468-1484
6. Bailey S. Violent children: a framework for assessment. Advances in Psychiatric Treatment 8 (2002) 97-106
7. Johnson J.G., Cohen P., Smailes E., et al. Adolescent personality disorders associated with violence and criminal behavior during adolescence and early adulthood. Am J Psychiatry 157 9 (2000) 1406-1412
8. Swartz M.S., Swanson J.W., Hiday V.A., et al. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry 155 (1998) 226-231
9. Guevara J.P., Mandell D.S., Rostain A.L., et al. National estimates of health services expenditures for children with behavioral disorders: an analysis of the Medical Expenditure Panel survey. Pediatrics 112 (2003) 440-446
10. Williams J., Klinepeter K., Palmes G., et al. Diagnosis and treatment of behavioral health disorders in pediatric practice. Pediatrics 114 3 (2004) 601-606
11. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry 36 Suppl 10 (1997) 122S-139S
12. Gosalakkal J.A. Aggression, rage and dyscontrol in neurological diseases of children. Journal of Pediatric Neurology 1 1 (2003) 9-14
13. Stone J., and Moran G. The utility of EEG in psychiatry and aggression. Psychiatr Bull R Coll Psychiatr 27 (2003) 171-172
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (2000), American Psychiatric Association, Washington (DC)
15. McElroy S.L., Soutullo C.A., Beckman D.A., et al. DSM-IV intermittent explosive disorder: a report of 27 cases. J Clin Psychiatry 59 (1998) 203-210
16. McElroy S.L. Recognition and treatment of DSM-IV intermittent explosive disorder. J Clin Psychiatry 60 Suppl 15 (1999) 12-16
17. Olvera R.L. Intermittent explosive disorder: epidemiology, diagnosis and management. CNS Drugs 16 8 (2002) 517-526
18. Findling R.L. Treatment of aggression in children. Prim Care Companion J Clin Psychiatry 5 Suppl 6 (2003) 5-9
19. Farmer E.M.Z., Compton S.N., Burns B.J., et al. Review of the evidence base for treatment of childhood psychopathology: externalizing disorders. J Consult Clin Psychol 70 6 (2002) 1267-1302
20. Heyneman E.K. The aggressive child. Child Adolesc Psychiatr Clin N Am 12 4 (2003) 667-677
21. Weisbrot D.M., and Ettinger A.B. Aggression and violence in mood disorders. Child Adolesc Psychiatr Clin N Am 11 3 (2002) 649-671
22. Gunnell D., and Ashby D. Antidepressants and suicide: what is the balance of benefit and harm?. BMJ 329 7456 (2004) 34-38
23. Walsh M.T., and Dinan T.G. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand 104 2 (2001) 84-91
24. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 9418 (2004) 1341-1345
25. Birmaher B., Ryan N.D., Williamson D.E., et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 35 11 (1996) 1427-1439
26. Geller B., Zimerman B., Williams M., et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 158 (2001) 125-127
27. Leibenluft E., Blair R.J.R., Charney D.S., et al. Irritability in pediatric mania and other childhood psychopathology. Ann N Y Acad Sci 1008 (2003) 201-218
28. Feldmann T.B. Bipolar disorder and violence. Psychiatr Q 72 2 (2001) 119-129
29. Sheard M.H., Marini J.L., Bridges C.I., et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 133 12 (1976) 1409-1413
30. Vetro A., Szentistvanyi I., Pallag L., et al. Therapeutic experience with lithium in childhood aggressivity. Neuropsychobiology 14 3 (1985) 121-127
31. Silva R.R., Ernst M., and Campbell M. Lithium and conduct disorder. Encephale 19 (1993) 585-590
32. Scahill L., Farkas L., and Hamrin V. Lithium in children and adolescents. J Child Adolesc Psychiatr Nurs 14 2 (2001) 89-93
33. Young J.L., and Hillbrand M. Carbamazepine lowers aggression: a review. Bull Am Acad Psychiatry Law 22 1 (1994) 53-61
34. Kafantaris V., Campbell M., Padron-Gayol M.V., et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 28 2 (1992) 193-199
35. Cueva J.E., Overall J.E., Small A.M., et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 35 4 (1996) 480-490
36. Seth R.D. Metabolic concerns associated with antiepileptic medications. Neurology 63 Suppl 4 (2004) S24-S29
37. Donovan S.J., Susser E.S., Nunes E.V., et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 58 1 (1997) 12-15
38. Donovan S.J., Stewart J.W., Nunes E.V., et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157 5 (2000) 818-820
39. Steiner H., Petersen M.L., Saxena K., et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 64 10 (2003) 1183-1191
40. Lehman R.B. Effectiveness of divalproex in the treatment of disruptive behavior disorders in children: a retrospective chart review. Primary Psychiatry 11 10 (2004) 48-52
41. Hellings J.A., Weckbaugh M., Nickel E.J., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15 4 (2005) 682-692
42. Verrotti A., Basciani F., De Simone M., et al. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 17 4 (2002) 265-268
43. Schmidt D., and Elger C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav 5 (2004) 627-635
44. Gaudino M.P., Smith M.J., and Matthews D.T. Use of oxcarbazepine for treatment-resistant aggression. Psychiatr Serv 54 8 (2003) 1166-1167
45. Aman M.G., De Smedt G., Derivan A., et al. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 15 8 (2002) 1337-1346
46. Snyder R., Turgay A., Aman M., et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41 9 (2002) 1026-1036
47. Findling R.L., Aman M.G., Eerdekens M., et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161 4 (2004) 677-684
48. Shea S., Turgay A., Carroll A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 5 (October 2004) e634-e641
49. Croonenberghs J., Fegert J.M., Findling R.L., et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44 1 (2005) 64-72
50. Findling R.L., McNamara N.K., Branicky L.A., et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39 4 (2000) 509-516
51. Pappagallo M., and Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 14 3 (2004) 359-371
52. Soderstrom H., Rastam M., and Gillberg C. A clinical case series of six extremely aggressive youths treated with olanzapine. Eur Child Adolesc Psychiatry 11 3 (2002) 138-141
53. Stigler K.A., Potenza M.N., Posey D.J., et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 6 1 (2004) 33-44
54. Staller J.A. Intramuscular ziprasidone in youth: a retrospective chart review. J Child Adolesc Psychopharmacol 14 4 (2004) 590-592
55. Hazaray E., Ehret J., Posey D.J., et al. Intramuscular ziprasidone for acute agitation in adolescents. J Child Adolesc Psychopharmacol 14 3 (2004) 464-470
56. Blair J., Scahill L., State M., et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44 1 (2005) 73-79
57. Corson A.H., Barkenbus J.E., Posey D.J., et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65 11 (2004) 1531-1536
58. Rugino T.A., and Janvier Y.M. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 20 7 (2005) 603-610
59. GlaxoSmithKline. Thorazine prescribing information; April 2002. Available at: http://us.gsk.com/products/assets/us_thorazine.pdf. Accessed November 4, 2005.
60. Busch B., Biederman J., Cohen L.G., et al. Correlates of ADHD among children in pediatric and psychiatry clinics. Psychiatr Serv 53 9 (2002) 1103-1111
61. Kutcher S., Aman M., Brooks S.J., et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14 1 (2004) 11-28
62. Roza S.J., Hofstra M.B., van der Ende J., et al. Stable prediction of mood and anxiety disorders based on behavioral and emotional problems in childhood: a 14-year follow-up during childhood, adolescence, and young adulthood. Am J Psychiatry 160 (2003) 2116-2121
63. Achenbach T.M. Manual for the child behavior checklist/4-18 and 1991 profile (1991), Department of Psychiatry, University of Vermont, Burlington (VT)
64. Fehon D.C., Grilo C.M., and Lipschitz D.S. A comparison of adolescent inpatients with and without a history of violence perpetration. Impulsivity, PTSD, and violence risk. J Nerv Ment Dis 193 (2005) 405-411
65. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 36 Suppl 10 (1997) 69S-84S
66. Bond A.J. Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications. CNS Drugs 9 1 (1998) 41-57
67. Gutierrez M.A., Roper J.M., and Hahn P. Paradoxical reactions to benzodiazepines. Am J Nurs 101 7 (2001) 34-39
68. Drummer O.H. Benzodiazepines-effects on human performance and behavior. Forensic Science Review 14 1 (2002) 1-14
69. Yorbik O., and Birmaher B. Pharmacological treatment of anxiety disorders in children and adolescents. Bulletin of Clinical Psychopharmacology 13 (2003) 133-141
70. Witek M.W., Rojas V., Alonso C., et al. Review of benzodiazepine use in children and adolescents. Psychiatr Q 76 3 (2005) 283-296
71. Neppe V.M., and Young Z.O. Buspirone as a new treatment for attention deficit disorder and aggression in children and adolescents. Australian Journal of Psychopharmacology 10 9 (2003) 47-56
72. Pfeffer C.R., Jiang H., and Domeshek L.J. Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression. J Child Adolesc Psychopharmacol 7 3 (1997) 145-155
73. Mattes J.A. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 2 2 (1990) 159-164
74. Hunt R.D., Minderaa R.B., and Cohen D.J. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24 5 (1985) 617-629
75. Connor D.F., Barkley R.A., and Davis H.T. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 39 1 (2000) 15-25
76. Hazell P.L., and Stuart J.E. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42 8 (2003) 886-894